What is Cabozantinib and what is its treatment
Cabozantinib is a multi-target tyrosine kinase inhibitor with broad-spectrum anti-cancer effects, known as the "panacea" of targeted drugs. This drug was developed by Exelixis in the United States and was approved by the FDA in 2012. It is suitable for the treatment of various malignant tumors such as medullary thyroid cancer and renal cell carcinoma.
1. Basic information of the drug
Cabozantinib is commonly known as Cabozantinib and marketed as Cabometyx. It blocks tumor angiogenesis and metastasis by inhibiting the activity of receptor tyrosine kinases such as MET and VEGFR.
2 main indications
(1) Medullary thyroid carcinoma
Used for the treatment of progressive and metastatic medullary thyroid cancer, approved for improvement in progression free survival and designated as an orphan drug by the FDA.
(2) Differentiated thyroid cancer
Suitable for locally advanced or metastatic differentiated thyroid cancer in patients aged 12 years and above who are refractory to radioactive iodine treatment.
(3) Renal cell carcinoma
Single drug or combination therapy with nivolumab is recommended for the treatment of advanced renal cell carcinoma in both untreated and treated patients according to guidelines.
(4) Hepatocellular carcinoma
Used for hepatocellular carcinoma patients treated with sorafenib and designated as an orphan drug by the FDA.
3 dosage form specifications
There are currently two dosage forms: capsules and tablets, with tablets available in two sizes: 20mg and 60mg.
4 target points of action
It can inhibit 13 receptor tyrosine kinases including MET, VEGFR-1/2/3, AXL, RET, ROS1, etc., achieving a multi-channel anti-tumor effect.
Disclaimer：《What is Cabozantinib and what is its treatment》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！